27313614|t|Frequency of BCR-ABL Transcript Types in Syrian CML Patients
27313614|a|Background. In Syria, CML patients are started on tyrosine kinase inhibitors (TKIs) and monitored until complete molecular response is achieved. BCR-ABL mRNA transcript type is not routinely identified, contrary to the recommendations. In this study we aimed to identify the frequency of different BCR-ABL transcripts in Syrian CML patients and highlight their significance on monitoring and treatment protocols. Methods. CML patients positive for BCR-ABL transcripts by quantitative RT-PCR were enrolled. BCR-ABL transcript types were investigated using a home-made PCR method that was adapted from published protocols and optimized. The transcript types were then confirmed using a commercially available research kit. Results. Twenty-four transcripts were found in 21 patients. The most common was b2a2, followed by b3a2, b3a3, and e1a3 present solely in 12 (57.1%), 3 (14.3%), 2 (9.5%), and 1 (4.8%), respectively. Three samples (14.3%) contained dual transcripts. While b3a2 transcript was apparently associated with warning molecular response to imatinib treatment, b2a2, b3a3, and e1a3 transcripts collectively proved otherwise (P = 0.047). Conclusion. It might be advisable to identify the BCR-ABL transcript type in CML patients at diagnosis, using an empirically verified method, in order to link the detected transcript with the clinical findings, possible resistance to treatment, and appropriate monitoring methods.
27313614	13	20	BCR-ABL	T017	UMLS:C1835417
27313614	21	31	Transcript	T103	UMLS:C1519595
27313614	41	47	Syrian	T098	UMLS:C0337819
27313614	48	51	CML	T038	UMLS:C0023473
27313614	76	81	Syria	T082	UMLS:C0039138
27313614	83	86	CML	T038	UMLS:C0023473
27313614	111	137	tyrosine kinase inhibitors	T038	UMLS:C2757011
27313614	139	143	TKIs	T038	UMLS:C2757011
27313614	174	192	molecular response	T033	UMLS:C4054479
27313614	206	213	BCR-ABL	T017	UMLS:C1835417
27313614	214	218	mRNA	T103	UMLS:C0035696
27313614	219	229	transcript	T103	UMLS:C1519595
27313614	359	366	BCR-ABL	T017	UMLS:C1835417
27313614	367	378	transcripts	T103	UMLS:C1519595
27313614	382	388	Syrian	T098	UMLS:C0337819
27313614	389	392	CML	T038	UMLS:C0023473
27313614	453	472	treatment protocols	T058	UMLS:C0040808
27313614	483	486	CML	T038	UMLS:C0023473
27313614	496	504	positive	T033	UMLS:C1446409
27313614	509	516	BCR-ABL	T017	UMLS:C1835417
27313614	517	528	transcripts	T103	UMLS:C1519595
27313614	545	551	RT-PCR	T062	UMLS:C0599161
27313614	567	574	BCR-ABL	T017	UMLS:C1835417
27313614	575	585	transcript	T103	UMLS:C1519595
27313614	628	631	PCR	T062	UMLS:C0032520
27313614	661	680	published protocols	T170	UMLS:C0936005
27313614	700	710	transcript	T103	UMLS:C1519595
27313614	768	780	research kit	T074	UMLS:C0812225
27313614	803	814	transcripts	T103	UMLS:C1519595
27313614	886	890	b3a3	T103	UMLS:C1519595
27313614	896	900	e1a3	T103	UMLS:C1519595
27313614	1017	1028	transcripts	T103	UMLS:C1519595
27313614	1091	1109	molecular response	T033	UMLS:C4054479
27313614	1113	1121	imatinib	T103	UMLS:C0935989
27313614	1122	1131	treatment	T058	UMLS:C0087111
27313614	1139	1143	b3a3	T103	UMLS:C1519595
27313614	1149	1165	e1a3 transcripts	T103	UMLS:C1519595
27313614	1259	1266	BCR-ABL	T017	UMLS:C1835417
27313614	1267	1277	transcript	T103	UMLS:C1519595
27313614	1286	1289	CML	T038	UMLS:C0023473
27313614	1381	1391	transcript	T103	UMLS:C1519595
27313614	1401	1418	clinical findings	T170	UMLS:C0455712
27313614	1443	1452	treatment	T058	UMLS:C0087111
27313614	1470	1488	monitoring methods	T058	UMLS:C1283169